Department of Pharmacy Administration, University of Illinois at Chicago, College of Pharmacy, 60612, USA.
Am J Alzheimers Dis Other Demen. 2011 Dec;26(8):606-15. doi: 10.1177/1533317511432734. Epub 2011 Dec 28.
This study provides empirical evidence on whether polypharmacy and potentially inappropriate prescription medications (PIRx, as defined by the 2003 Beers criteria) increase the likelihood of functional decline among community-dwelling older adults with dementia. Data were from the National Alzheimer's Coordinating Center, Uniform Data Set (9/2005-9/2009). Study sample included 1994 community-dwelling participants aged ≥65 with dementia at baseline. Results showed that participants having ≥5 medications were more likely to have functional decline than participants having <5 medications. However, the increased likelihood was only apparent in participants who did not have PIRx. Instead of magnifying the associated risk as hypothesized, PIRx appeared to have a protective effect albeit marginally statistically significant. Therefore, increased medication burden may be associated with functional decline in community-dwelling older adults with dementia who are not prescribed with PIRx. More research is needed to understand which classes of medications have the most deleterious effect on this population.
本研究提供了经验证据,证明多药治疗和潜在不适当处方药物(PIRx,根据 2003 年 Beers 标准定义)是否会增加患有痴呆症的社区居住老年人功能下降的可能性。数据来自国家阿尔茨海默病协调中心统一数据集(2005 年 9 月至 2009 年 9 月)。研究样本包括 1994 名基线时患有痴呆症且年龄在 65 岁及以上的社区居住参与者。结果表明,与使用<5 种药物的参与者相比,使用≥5 种药物的参与者更有可能出现功能下降。然而,这种可能性的增加仅在没有 PIRx 的参与者中明显。PIRx 似乎没有像假设的那样放大相关风险,而是具有保护作用,尽管在统计学上略有显著。因此,对于未开具 PIRx 的患有痴呆症的社区居住老年人,增加药物负担可能与功能下降有关。需要进一步研究以了解哪些类别的药物对这一人群的影响最大。